27 Mar 2014

Participants sought: Investigating Ondansetron for chronic residual schizophrenia

The purpose of this study is to investigate the use of the medication Ondansetron as an adjunctive or add-on therapy to existing anti-psychotic medication in the treatment of schizophrenia symptoms. Ondansetron is a well established medication which is approved in Australia for the treatment of drug-induced nausea and vomiting. However, various case studies and clinical studies have shown Ondansetron to also be effective in the treatment of symptoms associated with persistent schizophrenia.
This study will examine whether Ondansetron in combination with standard antipsychotic medication is more effective in improving the symptoms of schizophrenia than antipsychotic medication alone.

Contact
Mr Daniel Grice on (03) 9076 6581or email participate.maprc@monash.edu

Website link: http://www.maprc.org.au/current-projects-schizophr...
Related Posts Plugin for WordPress, Blogger...